filmov
tv
M4K Pharma Open Scientific Update Meeting December 2024- Recording
Показать описание
Recording of M4K Pharma's Scientific Update Meeting - December 17, 2024.
Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer.
1. Greetings and Agenda (00:00)
2. Funding Updates (03:20)
3. Compound Synthesis: Scale up batches of M4K2281 (5g) and M4K2308 (5g and 10g) were completed (08:20)
4. ADME/DMPK Update:
a) Ahmed presented a dose-escalation comparison between M4K2009 and M4K2308. He also presented a recent PK study at 10mg/kg with M4K2308 to measure the brain/plasma ratio. (09:45)
b) Divya provided an update on the analysis of historical and recent PK data related to target coverage in the brain for M4K2308. (14:29)
4. Proposed animal studies:
a) Plans are in place to run M4K2009, M4K2281, and M4K2308 at the University of Pennsylvania in Eileen Shore’s lab. (42:42)
b) Rebecca presented data on expression data in DIPG cell lines for efflux pumps ABCB1 and ABCG2. (46:04)
c) Tolerability studies with M4K2281 and M4K2308 at 25, 50 and 100 mg/kg are planned for January in non-tumour bearing NSG and C57BI/6s mice. (48:06)
d) Two concurrent in vivo studies are planned (54:02) :
- M4K2281 and M4K2009, 50 mg/kg 5d on/2 d off in an HSJD-DIPG-007
model (Maria Tsoli, Zeigler Lab, CCI, Australia)
- M4K2009, M4K2281 and M4K2308 50 mg/kg 5d on/2 d off in OB3-RCAS
model (ICR).
5.Data Gaps for M4K2308 and M4K 2281
a) A comparison table for lead series compounds M4K2009, M4K2163, M4K2281, M4K2308 was presented. We have deprioritized M4K2163 due to high protein binding and higher potential for cardiac liability compared to the other three. (1:05:23)
b) New data for M4K2308 CYP inhibition, AMES and dose linearity, all met TPP criteria. (1:06:07)
c) There was discussion on increasing efforts on M4K2281, with agreement that we should fill any data gaps for the compound. (1:06:30)
Everyone is invited to dial-in and join the live meetings.
To find out when our next meeting will be, follow us on:
Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer.
1. Greetings and Agenda (00:00)
2. Funding Updates (03:20)
3. Compound Synthesis: Scale up batches of M4K2281 (5g) and M4K2308 (5g and 10g) were completed (08:20)
4. ADME/DMPK Update:
a) Ahmed presented a dose-escalation comparison between M4K2009 and M4K2308. He also presented a recent PK study at 10mg/kg with M4K2308 to measure the brain/plasma ratio. (09:45)
b) Divya provided an update on the analysis of historical and recent PK data related to target coverage in the brain for M4K2308. (14:29)
4. Proposed animal studies:
a) Plans are in place to run M4K2009, M4K2281, and M4K2308 at the University of Pennsylvania in Eileen Shore’s lab. (42:42)
b) Rebecca presented data on expression data in DIPG cell lines for efflux pumps ABCB1 and ABCG2. (46:04)
c) Tolerability studies with M4K2281 and M4K2308 at 25, 50 and 100 mg/kg are planned for January in non-tumour bearing NSG and C57BI/6s mice. (48:06)
d) Two concurrent in vivo studies are planned (54:02) :
- M4K2281 and M4K2009, 50 mg/kg 5d on/2 d off in an HSJD-DIPG-007
model (Maria Tsoli, Zeigler Lab, CCI, Australia)
- M4K2009, M4K2281 and M4K2308 50 mg/kg 5d on/2 d off in OB3-RCAS
model (ICR).
5.Data Gaps for M4K2308 and M4K 2281
a) A comparison table for lead series compounds M4K2009, M4K2163, M4K2281, M4K2308 was presented. We have deprioritized M4K2163 due to high protein binding and higher potential for cardiac liability compared to the other three. (1:05:23)
b) New data for M4K2308 CYP inhibition, AMES and dose linearity, all met TPP criteria. (1:06:07)
c) There was discussion on increasing efforts on M4K2281, with agreement that we should fill any data gaps for the compound. (1:06:30)
Everyone is invited to dial-in and join the live meetings.
To find out when our next meeting will be, follow us on:
1:14:34
0:35:23
1:10:07
1:00:46
1:06:32
1:28:30
1:15:57
2:03:23
1:06:00
1:05:44
1:55:20
1:15:35
1:40:48
2:02:50
1:24:14
1:29:53
1:42:05
1:54:56
1:22:22
1:01:18
1:15:43
1:45:54
1:05:59
1:49:50